GlassScriptPhysician profile
Perisco A Wofford
NPI 1922000918
$7,849.81
in general payments reported to CMS, 2019-2025
26 companies · $4,159 in 2025
The $4,159 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $873 · 2020: $161 · 2021: $386 · 2022: $1,249 · 2023: $802 · 2024: $219 · 2025: $4,159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,543 · Food and Beverage: $1,617 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,542.50 |
| Food and Beverage | $1,617.14 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $3,598.30 | 2025 | |
| Glaxosmithkline, LLC. | $574.30 | 2022-2025 | |
| Novo Nordisk INC | $378.38 | 2020-2025 | |
| Vifor Pharma, INC. | $336.49 | 2019-2023 | Korsuva, Veltassa |
| Astrazeneca Pharmaceuticals LP | $317.82 | 2019-2023 | Farxiga |
| Ardelyx, INC. | $264.52 | 2023-2025 | Xphozah 30 Mg, Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $258.93 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $215.50 | 2019 | |
| Mallinckrodt Hospital Products INC. | $199.99 | 2022-2023 | Acthar |
| Otsuka America Pharmaceutical, INC. | $167.98 | 2019 | |
| Aurinia Pharma U.S., INC. | $154.59 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $145.61 | 2025 | Onpattro |
| Abbott Laboratories | $143.75 | 2022 | |
| Nxstage Medical, INC. | $135.62 | 2023 | Liberty Select Cycler, Nxstage System One |
| Horizon Therapeutics Plc | $132.13 | 2023 | Krystexxa |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $120.40 | 2019 | |
| Esperion Therapeutics, INC. | $118.15 | 2021 | |
| Alexion Pharmaceuticals, INC. | $115.05 | 2022 | |
| Edwards Lifesciences Corporation | $109.09 | 2025 | Sapien 3 Ultra Resilia |
| Veloxis Pharmaceuticals, INC. | $95.84 | 2022 | |
| Amgen INC. | $72.02 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $62.42 | 2024 | |
| Pfizer INC. | $51.52 | 2019 | |
| Fresenius USA Marketing, INC. | $34.03 | 2021-2022 | |
| Akebia Therapeutics INC | $24.83 | 2022 | |
| Opko Pharmaceuticals, LLC | $22.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Perisco Wofford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.